title: Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
abstract: OBJECTIVE
  Tacrolimus is an immunosuppressive drug used for the prevention of the allograft rejection in kidney transplant recipients. It exhibits a narrow therapeutic index and large pharmacokinetic variability. Tacrolimus is mainly metabolized by cytochrome P450 (CYP) 3A4 and 3A5 and effluxed via ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), encoded by ABCB1 gene. The influence of CYP3A5*3 on the pharmacokinetics of tacrolimus has been well characterized. On the other hand, the contribution of polymorphisms in other genes is controversial. In addition, the involvement of other efflux transporters than P-gp in tacrolimus disposition is uncertain. The present study was designed to investigate the effects of genetic polymorphisms of CYP3As and efflux transporters on the pharmacokinetics of tacrolimus.
  
  
  METHODS
  A total of 500 blood concentrations of tacrolimus from 102 adult stable kidney transplant recipients were included in the analyses. Genetic polymorphisms in CYP3A4 and CYP3A5 genes were determined. In addition, the genes of efflux transporters including P-gp (ABCB1), multidrug resistance-associated protein (MRP2/ABCC2) and breast cancer resistance protein (BCRP/ABCG2) were genotyped. For ABCC2 gene, haplotypes were determined as follows: H1 (wild type), H2 (1249G>A), H9 (3972C>T) and H12 (-24C>T and 3972C>T). Population pharmacokinetic analysis was performed using nonlinear mixed effects modeling.
  
  
  RESULTS
  Analyses revealed that the CYP3A5 expressers (CYP3A5*1 carriers) and MRP2 high-activity group (ABCC2 H2/H2 and H1/H2) showed a decreased dose-normalized trough concentration of tacrolimus by 2.3-fold (p < 0.001) and 1.5-fold (p = 0.007), respectively. The pharmacokinetics of tacrolimus were best described using a two-compartment model with first order absorption and an absorption lag time. In the population pharmacokinetic analysis, CYP3A5 expressers and MRP2 high-activity groups were identified as the significant covariates for tacrolimus apparent clearance expressed as 20.7 × (age/50)(-0.78) × 2.03 (CYP3A5 expressers) × 1.40 (MRP2 high-activity group). No other CYP3A4, ABCB1 or ABCG2 polymorphisms were associated with the apparent clearance of tacrolimus.
  
  
  CONCLUSIONS
  This is the first report showing that MRP2/ABCC2 has a crucial impact on the pharmacokinetics of tacrolimus in a haplotype-specific manner. Determination of the ABCC2 as well as CYP3A5 genotype may be useful for more accurate tacrolimus dosage adjustment.
authors: Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, 7 Greenhouse Road, Kingston, RI 02881, USA.
authors: Ken
authors: K
authors: Ogasawara
authors: Shripad D
authors: SD
authors: Chitnis
authors: Reginald Y
authors: RY
authors: Gohh
authors: Uwe
authors: U
authors: Christians
authors: Fatemeh
authors: F
authors: Akhlaghi
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D000293:Adolescent; D000328:Adult; D000368:Aged; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D005260:Female; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D000089762:Multidrug Resistance-Associated Protein 2; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics*; D009363:Neoplasm Proteins / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D016559:Tacrolimus / Q000097:blood / Q000493:pharmacokinetics*; D055815:Young Adult
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D051544:Cytochrome P-450 CYP3A; D007166:Immunosuppressive Agents; D000089762:Multidrug Resistance-Associated Protein 2; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D009363:Neoplasm Proteins; D016559:Tacrolimus; C513055:ABCB1 protein, human; C000715087:ABCC2 protein, human; C116614:ABCG2 protein, human; C510164:CYP3A5 protein, human; C510163:CYP3A4 protein, human
references: Clin Pharmacol Ther. 2009 Dec;86(6):609-18
references: 19865079
references: Drugs. 2003;63(12):1247-97
references: 12790696
references: Clin Pharmacol Ther. 2005 May;77(5):373-87
references: 15900284
references: Ther Drug Monit. 2009 Dec;31(6):734-42
references: 19855314
references: Pharmacogenomics J. 2011 Feb;11(1):25-34
references: 20351751
references: Am J Transplant. 2012 Dec;12(12):3326-36
references: 22947444
references: Ther Drug Monit. 1999 Feb;21(1):8-16
references: 10051049
references: Ther Drug Monit. 2005 Aug;27(4):422-30
references: 16044097
references: Clin Pharmacol Ther. 2011 May;89(5):693-701
references: 21451505
references: Clin Pharmacol Ther. 2002 Dec;72(6):660-9
references: 12496747
references: Br J Clin Pharmacol. 2011 Mar;71(3):391-402
references: 21284698
references: Pharm Res. 2009 May;26(5):1270-82
references: 18958406
references: Clin Pharmacokinet. 2002;41(11):813-51
references: 12190331
references: Clin Pharmacokinet. 2010 Mar;49(3):141-75
references: 20170205
references: Clin Pharmacol Ther. 2006 Oct;80(4):331-45
references: 17015051
references: Transplantation. 2011 Feb 15;91(3):300-8
references: 21206424
references: Clin Pharmacokinet. 2009;48(12):805-16
references: 19902988
references: J Clin Pharmacol. 2012 Dec;52(12):1833-43
references: 22207766
references: Nat Genet. 2001 Apr;27(4):383-91
references: 11279519
references: Pharmacogenetics. 2001 Dec;11(9):773-9
references: 11740341
references: Clin Pharmacol Ther. 2007 Feb;81(2):228-34
references: 17192769
references: Drug Metab Dispos. 1992 Sep-Oct;20(5):753-61
references: 1385058
references: J Biol Chem. 1993 Mar 25;268(9):6077-80
references: 7681059
references: Bioinformatics. 2005 Jan 15;21(2):263-5
references: 15297300
references: Clin Pharmacokinet. 2004;43(10):623-53
references: 15244495
references: Xenobiotica. 2013 Jul;43(7):641-9
references: 23278282
references: Ther Drug Monit. 2007 Aug;29(4):391-8
references: 17667791
references: Drug Metab Dispos. 1995 Dec;23(12):1315-24
references: 8689938
references: N Engl J Med. 2004 Dec 23;351(26):2715-29
references: 15616206
references: Pharmacology. 2011;88(5-6):288-94
references: 22075549
references: Diabetologia. 1994 Jun;37(6):543-51
references: 7926337
references: Pharmacogenet Genomics. 2008 Apr;18(4):339-48
references: 18334918
references: Eur J Clin Pharmacol. 2012 May;68(5):671-80
references: 22101623
references: Pharmacol Ther. 2006 Jan;109(1-2):137-61
references: 16209890
references: Clin Chem. 2011 Nov;57(11):1574-83
references: 21903774
references: Br J Pharmacol. 1996 Apr;117(8):1730-4
references: 8732283